Our team has more than 100 publications in leading scientific journals worldwide.
Abstract Background and aims: Comprehensive assessment of pharmacotherapy effects on atherogenic parameters (AP) that influence the risk of cardiovascular disease …
Abstract Fecal biomarkers are becoming an important analytical tool since feces are in direct contact with the inflamed intestine and …
Abstract Introduction Empagliflozin and sacubitril/valsartan reduce cardiovascular mortality and heart failure hospitalization rates, but the effect of early initiation of …
Abstract There is growing evidence linking growth differentiation factor 15 (GDF15) to both metabolic dysfunction-associated steatotic liver disease (MASLD) and …
Abstract Background/Objectives: Assessing nutrient intake is essential for understanding body homeostasis and diet-health interactions. Traditional methods, such as dietary questionnaires …
Abstract Background: Empagliflozin and sacubitril/valsartan are established in heart failure treatment, but their effects after myocardial infarction (MI) are less …
Abstract Cardiovascular diseases keep being the leading cause of mortality in Spain. Efforts should be intensified to identify new risk …
Abstract Background and aims: We aimed to assess the associations of exposure to air pollutants and standard and advanced lipoprotein …
Abstract Background and aim: Triglycerides (TG) are independent cardiovascular risk markers, yet TG-lowering therapies have failed to reduce major adverse …
Abstract Background and aims: Atherosclerotic cardiovascular disease (ASCVD) is among the leading causes of death worldwide, and technological advances have …